Karyopharm Therapeutics (KPTI) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$1.8 billion.
- Karyopharm Therapeutics' Retained Earnings fell 1512.93% to -$1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.8 billion, marking a year-over-year decrease of 1512.93%. This contributed to the annual value of -$1.8 billion for FY2025, which is 1512.93% down from last year.
- According to the latest figures from Q4 2025, Karyopharm Therapeutics' Retained Earnings is -$1.8 billion, which was down 1512.93% from -$1.7 billion recorded in Q3 2025.
- Karyopharm Therapeutics' 5-year Retained Earnings high stood at -$1.1 billion for Q1 2021, and its period low was -$1.8 billion during Q4 2025.
- Its 5-year average for Retained Earnings is -$1.4 billion, with a median of -$1.4 billion in 2023.
- Per our database at Business Quant, Karyopharm Therapeutics' Retained Earnings tumbled by 2004.87% in 2021 and then tumbled by 495.93% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Retained Earnings stood at -$1.2 billion in 2021, then dropped by 14.02% to -$1.3 billion in 2022, then decreased by 10.65% to -$1.5 billion in 2023, then fell by 5.14% to -$1.6 billion in 2024, then dropped by 15.13% to -$1.8 billion in 2025.
- Its Retained Earnings stands at -$1.8 billion for Q4 2025, versus -$1.7 billion for Q3 2025 and -$1.6 billion for Q2 2025.